vimarsana.com

Page 2 - Upifitamab Rilsodotin Upri News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Traders Purchase Large Volume of Call Options on Mersana Therapeutics (NASDAQ:MRSN)

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating) saw unusually large options trading activity on Thursday. Stock investors acquired 13,340 call options on the stock. This represents an increase of approximately 1,200% compared to the typical daily volume of 1,026 call options. Hedge Funds Weigh In On Mersana Therapeutics Institutional investors have recently bought and sold […]

Mersana Therapeutics (NASDAQ:MRSN) Shares Down 5 4%

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating) shares dropped 5.4% during trading on Tuesday . The stock traded as low as $7.14 and last traded at $7.16. Approximately 146,224 shares traded hands during mid-day trading, a decline of 91% from the average daily volume of 1,554,182 shares. The stock had previously closed at $7.57. Wall […]

Mersana Therapeutics (NASDAQ:MRSN) Shares Down 5 4%

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating) shares dropped 5.4% during trading on Tuesday . The stock traded as low as $7.14 and last traded at $7.16. Approximately 146,224 shares traded hands during mid-day trading, a decline of 91% from the average daily volume of 1,554,182 shares. The stock had previously closed at $7.57. Wall […]

Traders Buy High Volume of Call Options on Mersana Therapeutics (NASDAQ:MRSN)

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating) was the recipient of some unusual options trading activity on Wednesday. Investors acquired 2,225 call options on the company. This represents an increase of approximately 165% compared to the average daily volume of 840 call options. Mersana Therapeutics Trading Up 3.1 % Shares of NASDAQ:MRSN traded up $0.24 […]

Brokerages Set Mersana Therapeutics, Inc (NASDAQ:MRSN) PT at $14 71

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating) have earned a consensus rating of “Buy” from the seven brokerages that are presently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have updated their coverage on the stock […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.